
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows
Despite reporting positive Phase II results for its lead candidate last year, Vaccinex will soon no longer be a publicly traded company after falling short of Nasdaq requirements. The US-based company will delist its shares of common stock from Nasdaq via …